Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Summary

Cardiol Therapeutics filed a US$150 million preliminary base shelf prospectus with the Ontario Securities Commission, enabling the company to raise capital for its late-stage heart disease therapeutic programs.